Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J Spends $30 Billion on Switzerland’s Actelion

By Tom Murphy AP Health Writer | January 26, 2017

Johnson & Johnson is buying Swiss pharmaceutical Actelion in a $30 billion deal that will boost its treatments for life-threatening high blood pressure conditions.

The deal announced Thursday comes a little more than a month after J&J said it had ended talks to buy Actelion, and the Swiss company had said it was in discussions with another party.

The New Jersey maker of Band-Aids and prescription drugs said Thursday it will boost its portfolio of medicines and late-stage products in a complementary fit with Actelion’s area of expertise, pulmonary arterial hypertension, which is high blood pressure in the arteries between the heart and lungs.

Actelion products include Tracleer, an oral treatment sold in 60 markets.

The companies also will spin off Actelion’s research and development unit into a stand-alone company in Switzerland. J&J will own 16 percent of the business and have rights to an additional 16 percent.

J&J said funding for the acquisition will come from its holdings outside the United States. Many U.S. companies with international operations are holding sizeable amounts of money overseas due to high tax rates they would pay to return the cash to the United States.

Earlier in the week, J&J announced fourth-quarter profits that narrowly surpassed expectations, while giving Wall Street a softer-than-expected 2017 earnings forecast.

J&J has been dealing with sliding revenue from a top-selling drug, the biologic immune disorder treatment Remicade, which is facing competition from a Pfizer product.

With the Actelion deal, J&J is paying “top dollar” to replace Remicade sales, said Erik Gordon, a professor and pharmaceuticals analyst at University of Michigan’s Ross School of Business.

The New Brunswick, New Jersey, company made several deals in 2016, including a $3.3 billion purchase of hair and personal products maker Vogue International LLC.

In September, J&J — one of the 30 stocks that make up the Dow Jones Industrial Average — also said it would buy the medical optics division of Abbott Laboratories for $4.3 billion in cash.

The Actelion deal, approved unanimously by the boards of both companies, is to be completed in the second quarter, pending regulatory approvals, and J&J said it expects the deal to immediately boost revenues and earnings per share.

J&J shares slipped 52 cents to $112.28 in early morning U.S. trading Thursday.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE